CompanyHealthEnterprise
AvenCell Therapeutics
AvenCell Therapeutics is a clinical-stage cell therapy company building switchable, universal CAR-T treatments that can be turned 'off' and 'on' even after they are inside a patient. By pairing this controllable switch with a CRISPR-engineered, off-the-shelf allogeneic platform, AvenCell aims to widen the narrow safety window of conventional CAR-T while cutting the cost and wait time of manufacturing, targeting hard-to-treat blood cancers like AML, B-cell malignancies and, increasingly, autoimmune disease.
2021Founded
CambridgeHQ
up to $40 millionNon-dilutive grant (AvenCell Japan)
biotechnologycell-therapycar-tswitchable-car-toff-the-shelfallogeneic
